In 2018, BriaCell obtained topline safety and efficacy clinical data, achieved proof of concept and advanced its clinical program The company initiated patient dosing in a phase I/IIa clinical trial of its breast cancer immunotherapy Bria-IMT in combination with immune checkpoint inhibitors KEYTRUDA or YERVOY BriaCell is also working on the development of a personalized off-the-shelf […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.